Why the study?
Optimal treatment strategies for adults with congenital heart disease and atrial fibrillation are unknown.
Does cryoballoon pulmonary vein isolation with or without posterior wall isolation provide similar freedom from atrial tachyarrhythmia in adults with congenital heart disease compared to patients without congenital heart disease?
Does cryoballoon pulmonary vein isolation with or without posterior wall isolation provide similar freedom from atrial tachyarrhythmia in adults with congenital heart disease compared to patients without congenital heart disease?
Cryoballoon pulmonary vein isolation with or without posterior wall isolation is an effective treatment for atrial fibrillation in adults with congenital heart disease, yielding comparable 12-month outcomes to patients without congenital heart disease.
Introduction Optimal treatment strategies for ACHD with AF are unknown. This study sought to assess outcomes of pulmonary vein isolation (PVI) ± left atrial (LA), posterior wall isolation (PWI) for adults with congenital heart disease (ACHD), and atrial fibrillation (AF). Methods A retrospective review of all cryoballoon (CB) PVI ± PWI procedures at a single center over a 3‐year period were performed. Clinical characteristics and outcomes for patients with and without ACHD were compared. The primary outcome was the occurrence of atrial tachyarrhythmia at 12‐months postablation after a 90‐day blanking period. Results Three‐hundred and sixteen patients (mean: 63 ± 12 years, [63% male]) underwent CB PVI ± PWI during the study, including 31 (10%) ACHD (simple 35%, moderate 39% complex 26%; nonparoxysmal AF in 52%). ACHD was younger (51 vs. 64 years; p < .001) with a lower CHADS 2 DS 2 ‐VASc score (1.2 vs. 2.1; p = .001) but had a greater LA diameter (4.9 vs. 4.0 cm; p < .001) and a number of prior cardioversions (0.9 vs. 0.4; p < .001) versus controls. 12‐month freedom from recurrent AF was similar for ACHD and controls (76% vs. 80%; p = .6) and remained nonsignificant in multivariate analysis (hazard ratio: 1.8, 95% confidence interval: 0.7–5.1; p = .22). At 12‐months postablation, 75% of ACHD versus 93% of control patients were off antiarrhythmic drug therapy ( p = .07). Conclusion This study demonstrates younger age and lower conventional stroke risk, yet clinically advanced AF for ACHD relative to controls. CB PVI ± PWI was an effective strategy for the treatment of AF among all forms of ACHD with similar 12‐month outcomes as compared to controls.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: